Business Wire

Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay

Share

Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface skin cells stop performing at the same level, or “go to sleep,” causing fine lines, dehydration, and looser skin, in turn leading to skin looking and feeling less firm and more fragile.1

Skin Activator technology serves as a “wake-up call” to sleeping surface skin cells. The unique complex is powered by encapsulated CICA to help restore the skin’s moisture barrier to visibly plump and firm skin as well as microdosed mandelic acid to increase surface skin cell turnover to visibly reduce dull, uneven skin. In clinical trials, the Skin Activator Hydrating & Firming Lotion showed to be effective in improving the appearance of skin crepiness and smooth skin’s texture in one week. It was also proven to hydrate for firmer-looking skin in just four weeks. Moreover, when patients were asked about their experiences, 88% of Skin Activator Hydrating & Firming Cream users said their skin looked less crepey in 2 days, and 87% said their skin appeared more youthful after one week.2

“This launch signals a turning point in how we approach skin longevity. It’s more fundamental than wrinkles or loss of firmness, it’s about preserving surface skin health at the cellular level. As skin undergoes changes with age, it demands more precise, science-driven support. This insight fueled the development of our Skin Activator Hydrating & Firming line: a dermatologist-developed routine designed to strengthen, revitalize, and transform skin’s appearance.”

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS
CHIEF SCIENTIFIC OFFICER GALDERMA
HEAD OF INNOVATION, DERMATOLOGICAL SKINCARE

In developing the Skin Activator Hydrating & Firming Line, Galderma partnered with a medical advisory board of leading dermatologists.

“As a dermatologist, I’m always looking for what’s next in skin science, especially when it comes to aging. That’s why I was so excited to work with Cetaphil on the Skin Activator Hydrating & Firming line. We took on one of the biggest underlying causes of visible aging: surface skin health and cell senescence. By targeting these ‘zombie cells,’ we’re helping to support skin renewal in a way that’s truly backed by science. It’s been incredibly rewarding to help bring that kind of innovation to a skincare routine patients can use all over, every day.”

DR. GLYNIS ABLON*
BOARD-CERTIFIED DERMATOLOGIST
ASSOCIATE CLINICAL PROFESSOR, UNIVERSITY OF CALIFORNIA, LOS ANGELES

A new era of skin activation, backed by science and brought to life by a cultural icon
To help bring this segment-defining line to life, Cetaphil is proud to partner with acclaimed actress, director, and advocate, Mariska Hargitay. Known for her strength, compassion, and authenticity, Hargitay represents a powerful voice in embracing beauty at every stage of life. As the face of the campaign, she will help share a message of empowerment and reinvention – giving women the tools to reawaken both their skin’s look and their aspirations. Hargitay’s partnership will span across a robust marketing effort, inclusive of PR, advertising, in-store, retailer e-commerce, and social.

Fragrance-free, non-comedogenic, and hypoallergenic, the Skin Activator Hydrating & Firming line also embraces the trending notion of “skinification,” or using facial care-inspired ingredients to address full-body skincare needs. Products within the newly launched Skin Activator Hydrating & Firming Line include:

  • Cetaphil Hydrating & Firming Cream for Neck, Chest, and Face (3.4 oz.)
  • Cetaphil Hydrating & Firming Cream for Body (12 oz.)
  • Cetaphil Hydrating & Firming Lotion (16 oz.)

The Hydrating & Firming Line is now widely available for purchase in the United States. Galderma is working to bring this new innovation to other international markets where Cetaphil is already available. See full list of retailers here: https://www.cetaphil.com/us/where-buy. For more information, consumers can also follow Cetaphil on Instagram (@Cetaphil) and TikTok (@Cetaphil) or visit www.cetaphil.com.

About Cetaphil®
Over seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula that would clean without stripping and moisturize without clogging. Today, Cetaphil is a dermatologist recommended sensitive skincare brand and is recognized around the world. With the help of leading global skincare experts, they continue to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin's health every day. For more information, visit www.cetaphil.com.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermato-logical Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References and disclaimers:

  1. Novel Strategy for Strengthening Dermatoporotic Skin by Managing Cellular Senescence. J Drugs Dermatol. 2024 Sep 1;23(9):748-756. doi: 10.36849/JDD.8388.
  2. Galderma 12-week in-use study-consumer data questionnaire. Subject data on file.

* Paid Galderma Consultant; Galderma Clinical Study investigator for the Cetaphil hydrating & firming product line

View source version on businesswire.com: https://www.businesswire.com/news/home/20250917102132/en/

Contacts

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Jeffrey Smith
Head of U.S. Communications
jeffrey.smith@galderma.com
+ 1 (682) 401-8428

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release

AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by

illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release

illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont

Textron Aviation Broadens Aftermarket Connectivity Solutions for Cessna Citation Latitude by Offering Starlink High-Speed Internet18.9.2025 16:30:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an additional high-speed internet connectivity solution for the Cessna Citation Latitude following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918380069/en/ Textron Aviation broadens aftermarket connectivity solutions for Cessna Citation Latitude by offering Starlink high-speed internet (Photo Credit: Textron Aviation) “With Starlink connectivity now available as an upgrade, Citation Latitude customers can enjoy a seamless, high-speed in-flight experience that keeps them connected in more

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye